SpyGlass Pharma’s 10% owner Carmen Chang filed an initial ownership report detailing indirect stakes in multiple series of the company’s preferred stock. The preferred shares are held through New Enterprise Associates funds, including NEA 16 and NEA 17, via their general partner entities. All preferred shares will automatically convert on a one-for-one basis into SpyGlass Pharma common stock before the closing of its initial public offering. Chang disclaims beneficial ownership of portions of the NEA 16 and NEA 17 holdings in which she has no pecuniary interest.
SpyGlass Pharma, Inc. insider Florence Anthony A. Jr., a 10% owner, filed a Form 3 reporting indirect holdings of multiple preferred stock series. These include Series B preferred stock convertible into 1,619,240 shares of common stock and Series A preferred stock convertible into 954,990 common shares.
All reported preferred shares automatically convert into common stock on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering. The securities are directly owned by New Enterprise Associates funds, while Anthony serves in managing roles at their general partners and disclaims beneficial ownership where he has no pecuniary interest.
SpyGlass Pharma, Inc. director and 10% owner Ali Behbahani filed an initial Form 3 reporting indirect holdings of several series of preferred stock. These include 1,619,240 shares of Series B Preferred Stock and 954,990 shares of Series A Preferred Stock through New Enterprise Associates funds. All preferred shares will automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering. Behbahani reports these interests through NEA 16 and NEA 17 structures and disclaims beneficial ownership of portions in which he has no pecuniary interest.
SpyGlass Pharma, Inc. 10% owner Paul Edward Walker filed an initial ownership report showing indirect holdings of multiple series of preferred stock as of February 5, 2026. These include Series A, B, C-1, C-2 and D preferred shares, each convertible into common stock on a one-for-one basis before the company’s initial public offering.
The preferred shares reported are held through New Enterprise Associates funds NEA 16 and NEA 17, via their general partner entities. Walker is a manager of the relevant general partners and disclaims beneficial ownership of any portions in which he has no pecuniary interest.
SpyGlass Pharma 10% owner Scott D. Sandell filed an initial Form 3 reporting indirect holdings of multiple preferred stock series that are convertible into common shares. All preferred stock will automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering. The securities are directly held by New Enterprise Associates funds NEA 17 and NEA 16, with Sandell serving as a manager of their general partner entities and disclaiming beneficial ownership of portions in which he has no pecuniary interest.
SpyGlass Pharma, Inc. had several New Enterprise Associates entities file an initial Form 3 reporting their status as 10% owners as of February 5, 2026. The reporting persons are New Enterprise Associates 17, L.P., NEA Partners 17, L.P., and NEA 17 GP, LLC.
The holdings consist of multiple series of preferred stock that are convertible into SpyGlass Pharma common stock. NEA 17 directly holds Series B, Series C-1, Series C-2, and Series D Preferred Stock, which together correspond to 1,619,240, 1,370,168, 1,370,168 and 737,962 shares of common stock, respectively. All preferred shares will automatically convert one-for-one into common stock before the closing of SpyGlass Pharma’s initial public offering.
SpyGlass Pharma, Inc. received an initial ownership report from Edward T. Mathers as a 10% owner. The filing shows entities associated with him indirectly hold multiple series of preferred stock in SpyGlass.
These indirect holdings include 1,619,240 shares of Series B Preferred Stock, 1,370,168 shares of Series C-1 Preferred Stock, 1,370,168 shares of Series C-2 Preferred Stock, and 737,962 shares of Series D Preferred Stock, all held through New Enterprise Associates 17, L.P. The preferred shares will automatically convert into an equal number of common shares on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering of common stock.
SpyGlass Pharma, Inc. filed an initial ownership report for 10% owner Mohamad Makhzoumi, showing indirect holdings of multiple preferred stock series that are convertible into common shares. All preferred shares will automatically convert to common stock on a one-for-one basis before the closing of the company’s initial public offering.
The indirect holdings include Series A, B, C-1, C-2 and D preferred stock of SpyGlass Pharma. These securities are held through New Enterprise Associates funds NEA 16 and NEA 17, where related partnerships are the direct beneficial owners. The reporting person disclaims beneficial ownership of portions of these fund-held securities in which he has no pecuniary interest.
SpyGlass Pharma, Inc. received an initial Form 3 from investment entities associated with RA Capital Management, L.P. reporting indirect holdings of multiple series of preferred stock. These include Series C-1, Series C-2 and Series D preferred shares that are each convertible into SpyGlass common stock on a one-for-one basis before the closing of SpyGlass’s initial public offering. The preferred shares are held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., with RA Capital Management acting as investment manager. RA Capital, its related general partners, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest. Principal Zachary Scheiner of RA Capital serves on SpyGlass Pharma’s board of directors.
SpyGlass Pharma, Inc. director Dable Habib J filed an initial ownership report stating no securities are beneficially owned. This Form 3 establishes that, as of the reported date, the director holds no direct or indirect ownership of SpyGlass Pharma stock or derivative securities.